PI(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))

Term ID

CHEBI:88660

Synonyms

1-(9Z,12Z-Octadecadienoyl)-2-(8Z,11Z,14Z-eicosatrienoyl)-sn-glycero-3-phospho-(1'-myo-inositol)
1-Linoleoyl-2-homo-g-linolenoyl-sn-glycero-3-phosphoinositol
1-Linoleoyl-2-homo-gamma-linolenoyl-sn-glycero-3-phosphoinositol
[(2R)-2-[(8Z,11Z,14Z)-icosa-8,11,14-trienoyloxy]-3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propoxy]({[(1s,3R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid
Phosphatidylinositol(18:2/20:3)
Phosphatidylinositol(18:2n6/20:3n6)
Phosphatidylinositol(18:2w6/20:3w6)
Phosphatidylinositol(38:5)
PI(18:2/20:3)
PI(18:2n6/20:3n6)
PI(18:2w6/20:3w6)
PI(38:5)
PIno(18:2/20:3)
PIno(18:2n6/20:3n6)
PIno(18:2w6/20:3w6)
PIno(38:5)

(all 16)

Definition

References

(all 4)

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from PI(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))

Phenotype where environments contain PI(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))

Phenotype modified by environments containing PI(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))

Phenotype affecting PI(18:2(9Z,12Z)/20:3(8Z,11Z,14Z))

Human Disease Model